C9‐Functionalized Doxycycline Analogs as Drug Candidates to Prevent Pathological α‐Synuclein Aggregation and Neuroinflammation in Parkinson's Disease Degeneration
ChemMedChem · 2024
DOI: 10.1002/cmdc.202300597 ↗Kurz gefasst
Fachartikel in der Zeitschrift ChemMedChem, 2024. Verfasst von Clémence Rose und 8 weiteren Autor:innen. Beteiligte Einrichtung: BioCIS, CNRS, Université Paris-Saclay, 91400, Orsay, France. Hauptthemen laut MEDLINE: alpha-Synuclein, Doxycycline, Parkinson Disease, Protein Aggregates. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: French Association France Parkinson, Carnot Institute, Institut Carnot Santé Animale.
Abstract (Originalsprache)
Doxycycline, a semi‐synthetic tetracycline, is a widely used antibiotic for treating mild‐to‐moderate infections, including skin problems. However, its anti‐inflammatory and antioxidant properties, combined with its ability to interfere with α‐synuclein aggregation, make it an attractive candidate for repositioning in Parkinson's disease. Nevertheless, the antibiotic activity of doxycycline restricts its potential use for long‐term treatment of Parkinsonian patients. In the search for non‐antibiotic tetracyclines that could operate against Parkinson's disease pathomechanisms, eighteen novel doxycycline derivatives were designed. Specifically, the dimethyl‐amino group at C 4 was reduced, resulting in limited antimicrobial activity, and several coupling reactions were performed at position C 9 of the aromatic D ring, this position being one of the most reactive for introducing substituents. Using the Thioflavin‐T assay, we found seven compounds were more effective than doxycycline in inhibiting α‐synuclein aggregation. Furthermore, two of these derivatives exhibited better anti‐inflammatory effects than doxycycline in a culture system of microglial cells used to model Parkinson's disease neuroinflammatory processes. Overall, through structure‐activity relationship studies, we identified two newly designed tetracyclines as promising drug candidates for Parkinson's disease treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- BioCIS, CNRS, Université Paris-Saclay, 91400, Orsay, France.
- IMMCA, CONICET-UNT-SIPROSA, Tucumán, 4000, Argentina.
- Paris Brain Institute-ICM, Inserm, Sorbonne Université, CNRS, Hôpital Pitié Salpêtrière, 75013, Paris, France.
- UMR_MD1 Membranes et Cibles Thérapeutiques, U1261 INSERM, Aix-Marseille Université, 13385, Marseille, France.
ORCID-Profile: Rodrigo Hernán Tomas-Grau, Patrick Pierre Michel, Jean-Michel Brunel, Rosana Chehín, Rita Raisman-Vozari, Laurent Ferrié, Bruno Figadère
Förderung
- French Association France Parkinson
- Carnot Institute
- Institut Carnot Santé Animale
Zitieren
APA
Rose, C., Tomas-Grau, R. H., Zabala, B., Michel, P. P., Brunel, J. M., Chehín, R., Raisman-Vozari, R., Ferrié, L., & Figadère, B. (2024). C9‐Functionalized Doxycycline Analogs as Drug Candidates to Prevent Pathological α‐Synuclein Aggregation and Neuroinflammation in Parkinson's Disease Degeneration. ChemMedChem. https://doi.org/10.1002/cmdc.202300597
Vancouver
Rose C, Tomas-Grau RH, Zabala B, Michel PP, Brunel JM, Chehín R, et al. C9‐Functionalized Doxycycline Analogs as Drug Candidates to Prevent Pathological α‐Synuclein Aggregation and Neuroinflammation in Parkinson's Disease Degeneration. ChemMedChem. 2024. doi:10.1002/cmdc.202300597
BibTeX
@article{Rose2024,
author = {Rose, Clémence and Tomas-Grau, Rodrigo Hernán and Zabala, Brenda and Michel, Patrick Pierre and Brunel, Jean-Michel and Chehín, Rosana and Raisman-Vozari, Rita and Ferrié, Laurent and Figadère, Bruno},
title = {C9‐Functionalized Doxycycline Analogs as Drug Candidates to Prevent Pathological α‐Synuclein Aggregation and Neuroinflammation in Parkinson's Disease Degeneration},
journal = {ChemMedChem},
year = {2024},
doi = {10.1002/cmdc.202300597}
}
EUVIMED